Cargando…
Stimulated Reporting of Adverse Events Following Immunization with COVID-19 Vaccines
In India, up until December 2021, Covishield and Covaxin vaccines against COVID-19 were being used for mass vaccination programs. In view of the urgency of fighting the ongoing pandemic, many vaccines have been granted emergency use approval while phase 2/3 clinical trials were still underway. Even...
Autores principales: | Jhaj, Ratinder, Chaudhary, Deepa, Shukla, Ajay K., Yadav, Jayanthi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782407/ https://www.ncbi.nlm.nih.gov/pubmed/36560545 http://dx.doi.org/10.3390/vaccines10122133 |
Ejemplares similares
-
A case report on azathioprine-induced euprolactinemic galactorrhea
por: Chaudhary, Deepa, et al.
Publicado: (2021) -
Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions
por: Shukla, Ajay K., et al.
Publicado: (2021) -
Topical steroid containing combinations: Burden of adverse effects and why the recent regulatory action may not be enough
por: Jhaj, Ratinder, et al.
Publicado: (2021) -
Fixed drug eruption due to levocetirizine
por: Jhaj, Ratinder, et al.
Publicado: (2016) -
Fixed-drug Eruptions: What can we Learn from a Case Series?
por: Jhaj, Ratinder, et al.
Publicado: (2018)